Cellular Compositions and Methods of Treatment I
Summary
The USPTO published patent application US20260109981A1 on April 23, 2026, covering cellular compositions modified to deliver nucleic acids to target cells for the treatment of diseases including cancer. The application, filed September 16, 2025, names 11 inventors including Peter Brink, Ira Cohen, Richard Lin, and others. CPC classifications indicate focus areas in nucleic acid delivery, cell-based therapies, and oncology applications.
“The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 264 changes logged to date.
What changed
The USPTO published a new patent application (US20260109981A1, Kind A1) for cellular compositions modified to express nucleic acids or vectors, with utility in delivering therapeutic nucleic acids to target cells for disease treatment, notably cancer. The filing date was September 16, 2025, and the application is now publicly accessible in the USPTO database.
Affected parties include biotechnology and cell therapy developers working on nucleic acid delivery platforms, gene therapy researchers, and oncology treatment developers who may wish to evaluate freedom-to-operate or licensing opportunities related to this technology.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CELLULAR COMPOSITIONS AND METHODS OF TREATMENT I
Application US20260109981A1 Kind: A1 Apr 23, 2026
Inventors
Peter BRINK, Ira COHEN, Richard LIN, Sergey DORONIN, Irina POTAPOVA, Virginijus VALIUNAS, Dan DEVINE, Anthony SANDRASAGRA, Nick LOIZOS, Silviu ITESCU
Abstract
The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same. Such compositions may be used to deliver nucleic acid to a target cell and treat disease such as cancer.
CPC Classifications
C12N 15/113 A61K 35/28 A61K 38/45 A61P 35/00 C12Y 204/01214 C12N 2310/11 C12N 2310/141 C12N 2320/32
Filing Date
2025-09-16
Application No.
19330470
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.